EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Evaluating tixagevimab/cilgavimab prophylaxis in allogeneic haematopoietic cell transplantation recipients for COVID ‐19 prevention

Julia Trepl iD, Chloé Pasin iD, Dominik Schneidawind iD, Nicolas J Mueller, Markus G Manz, Andriyana K Bankova iD, Irene A Abela iD

British Journal of Haematology · 2024

DOI: 10.1111/bjh.19321 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Haematology, 2024. Verfasst von Julia Trepl und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland. Hauptthemen laut MEDLINE: Hematopoietic Stem Cell Transplantation, COVID-19, SARS-CoV-2, Antibodies, Monoclonal, Humanized. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Promedica foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Allogeneic haematopoietic cell transplantation (allo‐HCT) recipients exhibit an increased risk of COVID‐19, particularly in the early post‐transplant phase, due to insufficient vaccine responses. This retrospective study investigated the incidence of SARS‐CoV‐2 infection in allo‐HCT recipients who received tixagevimab/cilgavimab pre‐exposure prophylaxis (T/C PrEP) compared to those who did not. Logistic regression, adjusted for sex, age, SARS‐CoV‐2 vaccination status and immunosuppressive treatment, revealed a significant reduction in the likelihood of SARS‐CoV‐2 infection risk with T/C PrEP (adjusted odds ratio aOR = 0.26 [0.07, 0.91]). These findings suggest the potential efficacy of monoclonal antibody PrEP in protecting this vulnerable patient population from COVID‐19.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hematopoietic Stem Cell TransplantationCOVID-19SARS-CoV-2Antibodies, Monoclonal, HumanizedHumansMaleFemaleMiddle AgedAdultRetrospective StudiesAgedTransplantation, HomologousPre-Exposure ProphylaxisAllografts

Stichwörter der Autor:innen

COVID‐19SARS‐CoV‐2monoclonal antibodiesrisk factorsstem cell transplantation

Substanzen

Antibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Department of Medical Oncology and Hematology, University Hospital Zurich, Zurich, Switzerland.
  • Institute of Medical Virology, University of Zurich, Zurich, Switzerland.
  • Department of Infectious Diseases and Hospital Epidemiology, University Hospital Zurich, University of Zurich, Zurich, Switzerland.
  • National Specialized Hospital for Hematological Diseases, Sofia, Bulgaria.

ORCID-Profile: Julia Trepl, Chloé Pasin, Dominik Schneidawind, Andriyana K Bankova, Irene A Abela

Förderung

  • Promedica foundation

Zitieren

APA

Trepl, J., Pasin, C., Schneidawind, D., Mueller, N. J., Manz, M. G., Bankova, A. K., & Abela, I. A. (2024). Evaluating tixagevimab/cilgavimab prophylaxis in allogeneic haematopoietic cell transplantation recipients for COVID ‐19 prevention. British Journal of Haematology. https://doi.org/10.1111/bjh.19321

Vancouver

Trepl J, Pasin C, Schneidawind D, Mueller NJ, Manz MG, Bankova AK, et al. Evaluating tixagevimab/cilgavimab prophylaxis in allogeneic haematopoietic cell transplantation recipients for COVID ‐19 prevention. British Journal of Haematology. 2024. doi:10.1111/bjh.19321

BibTeX
@article{Trepl2024,
  author = {Trepl, Julia and Pasin, Chloé and Schneidawind, Dominik and Mueller, Nicolas J and Manz, Markus G and Bankova, Andriyana K and Abela, Irene A},
  title = {Evaluating tixagevimab/cilgavimab prophylaxis in allogeneic haematopoietic cell transplantation recipients for COVID ‐19 prevention},
  journal = {British Journal of Haematology},
  year = {2024},
  doi = {10.1111/bjh.19321}
}
Kostenlos starten →